Revolution Medicines (MIL:1RVMD) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1RVMD Revolution Medicines Inc MIL:1RVMD
9 GF Score
Price €159.95
GF Value €0.40
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Revolution Medicines Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Revolution Medicines Valuation Rank Related Terms

MIL:1RVMD
9GF Score
Revolution Medicines Inc MIL:1RVMD
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Revolution Medicines (MIL:1RVMD) Overvalued in 2026?

Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued. The current stock price of €159.95 is trading 39887.5% above its estimated GF Value™ of €0.40. GuruFocus considers Revolution Medicines to be Significantly Overvalued.

Key valuation signals for MIL:1RVMD:

  • Valuation Rank:
  • GF Value™: €0.40 vs. price of €159.95 (39887.5% above fair value)
  • GF Score™: 9/100 with 4 warning signs

No single metric tells the full story. See the MIL:1RVMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Revolution Medicines Business Description

Other Exchanges RVMD:USA42Z:Germany
Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
9GF Score

Get the complete analysis for MIL:1RVMD

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€159.95
Price
€0.40
GF Value